JP2013519636A5 - - Google Patents

Download PDF

Info

Publication number
JP2013519636A5
JP2013519636A5 JP2012552352A JP2012552352A JP2013519636A5 JP 2013519636 A5 JP2013519636 A5 JP 2013519636A5 JP 2012552352 A JP2012552352 A JP 2012552352A JP 2012552352 A JP2012552352 A JP 2012552352A JP 2013519636 A5 JP2013519636 A5 JP 2013519636A5
Authority
JP
Japan
Prior art keywords
fviii
domain
linked
psa
fviii variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012552352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013519636A (ja
JP5933457B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/051723 external-priority patent/WO2011101267A1/en
Publication of JP2013519636A publication Critical patent/JP2013519636A/ja
Publication of JP2013519636A5 publication Critical patent/JP2013519636A5/ja
Application granted granted Critical
Publication of JP5933457B2 publication Critical patent/JP5933457B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012552352A 2010-02-16 2011-02-07 コンジュゲートｆｖｉｉｉバリアント Expired - Fee Related JP5933457B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10153718.1 2010-02-16
EP10153718 2010-02-16
US30560810P 2010-02-18 2010-02-18
US61/305,608 2010-02-18
PCT/EP2011/051723 WO2011101267A1 (en) 2010-02-16 2011-02-07 Conjugated fviii variants

Publications (3)

Publication Number Publication Date
JP2013519636A JP2013519636A (ja) 2013-05-30
JP2013519636A5 true JP2013519636A5 (https=) 2014-03-27
JP5933457B2 JP5933457B2 (ja) 2016-06-08

Family

ID=42173354

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012553254A Expired - Fee Related JP5914363B2 (ja) 2010-02-16 2011-02-02 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
JP2012552352A Expired - Fee Related JP5933457B2 (ja) 2010-02-16 2011-02-07 コンジュゲートｆｖｉｉｉバリアント

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012553254A Expired - Fee Related JP5914363B2 (ja) 2010-02-16 2011-02-02 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子

Country Status (5)

Country Link
US (4) US20130040888A1 (https=)
EP (2) EP2536753B1 (https=)
JP (2) JP5914363B2 (https=)
CN (3) CN105524164A (https=)
WO (2) WO2011101242A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
CA2670618C (en) 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR101912335B1 (ko) 2009-07-27 2018-10-26 리폭센 테크놀로지즈 리미티드 비혈액 응고 단백질의 글리코폴리시알화
CN102497884A (zh) 2009-07-27 2012-06-13 巴克斯特国际公司 凝血蛋白缀合物
CN106110311A (zh) 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
DK2804623T3 (da) * 2012-01-12 2019-11-11 Bioverativ Therapeutics Inc Kimære faktor viii-polypeptider og anvendelser deraf
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
MY190257A (en) * 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
HRP20200007T1 (hr) * 2012-07-11 2020-03-20 Bioverativ Therapeutics Inc. Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
EP2906247A1 (en) 2012-10-15 2015-08-19 Novo Nordisk Health Care AG Factor vii conjugates
EP2796145B1 (en) * 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
JP6463361B2 (ja) * 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
EP3058066A1 (en) 2013-10-15 2016-08-24 Novo Nordisk Health Care AG Coagulation factor vii polypeptides
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
AR099328A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados de factor vii
AR101060A1 (es) * 2014-02-12 2016-11-23 Novo Nordisk As Conjugados de fviii
CN106459180A (zh) * 2014-03-23 2017-02-22 爱德技术生物科学有限公司 在铜使用下重组蛋白表达的增强
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10238718B2 (en) 2014-08-04 2019-03-26 Csl Limited Factor VIII formulation
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
EP3042952A1 (en) * 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
KR102799807B1 (ko) * 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
KR102219859B1 (ko) * 2016-06-24 2021-02-25 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물
CN109790529A (zh) 2016-06-24 2019-05-21 财团法人牧岩生命科学研究所 包含FVIII和vWF因子的嵌合蛋白及其用途
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3642225A1 (en) 2017-06-23 2020-04-29 Baxalta Incorporated Purification of factor viii subspecies
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
US12440572B2 (en) 2018-05-18 2025-10-14 Zhengzhou Gensciences Inc. FVIII fusion protein and use thereof
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
WO2021038296A2 (en) 2019-08-27 2021-03-04 Tonix Pharma Holdings Limited Modified tff2 polypeptides
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7680442B2 (ja) 2019-11-11 2025-05-20 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
AU2645588A (en) 1987-12-04 1989-06-15 Scripps Clinic And Research Foundation The von willebrand factor binding domain of factor viii
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1999055377A2 (en) 1998-04-28 1999-11-04 Applied Research Systems Ars Holding N.V. Polyol-ifn-beta conjugates
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
AU2002352524B2 (en) * 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
ATE371680T1 (de) 2002-01-16 2007-09-15 Biocompatibles Uk Ltd Polymerkonjugate
WO2005016974A1 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
CN101160326B (zh) 2005-02-23 2013-04-10 利普生技术有限公司 用于蛋白质衍生和缀合的活化的唾液酸衍生物
US20100143969A1 (en) 2005-03-24 2010-06-10 Neose Technologies, Inc. Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms
JP2008534559A (ja) * 2005-04-01 2008-08-28 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 血液凝固ｆｖｉｉｉ類似体
RU2007145085A (ru) 2005-06-15 2009-07-20 Ново Нордиск Хелс Кеа Аг (Ch) Опосредованное трансглютаминазой коньюгирование гормона роста
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
EP1981977B1 (en) 2006-01-31 2015-12-23 National Research Council Of Canada Production of polysialic acid containing glyconjugates using a self-priming polysialyltransferase
CA2647314A1 (en) 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
ES2516694T3 (es) 2006-07-21 2014-10-31 Ratiopharm Gmbh Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
CA2670618C (en) 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
EP2162535A4 (en) 2007-06-04 2011-02-23 Novo Nordisk As O-linked glycosylation using N-acetylglucosamine transferases
CA2689557C (en) 2007-06-15 2018-08-14 National Research Council Of Canada Engineered versions of polysialyltransferases with enhanced enzymatic properties
CA2704234A1 (en) * 2007-11-09 2009-05-14 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
CA2711503A1 (en) * 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
KR101582841B1 (ko) * 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 콘쥬게이트된 인자 ｖｉｉｉ 분자
KR101648734B1 (ko) 2008-06-24 2016-08-18 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
KR101929641B1 (ko) 2008-10-17 2018-12-14 박스알타 인코퍼레이티드 낮은 수준의 수용성 중합체를 포함하는 개질된 혈액 인자
EP2398822B1 (en) * 2009-02-19 2013-01-02 Novo Nordisk A/S Modification of factor viii
JP5770161B2 (ja) * 2009-04-06 2015-08-26 ノヴォ ノルディスク アー／エス 血小板への第ｖｉｉｉ因子タンパク質の標的送達
CN105153313A (zh) * 2010-02-16 2015-12-16 诺沃—诺迪斯克有限公司 因子viii融合蛋白

Similar Documents

Publication Publication Date Title
JP2013519636A5 (https=)
JP2013519697A5 (https=)
JP2010215657A5 (https=)
IN2014DN00101A (https=)
EA201890389A2 (ru) Композиции конъюгата xten и способы их получения
JP2012255007A5 (https=)
JP2011515499A5 (https=)
JP2015536943A5 (https=)
CR20110515A (es) Compuesto biocompatible y su uso
JP2015519313A5 (https=)
JP2012508172A5 (https=)
EA201170039A1 (ru) Полимерные частицы, нагруженные лекарственным средством, и способы их получения и применения
JP2014515039A5 (https=)
BR112012012210B8 (pt) conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
WO2010122385A8 (fr) Formulation a action rapide d'insuline
HK1205156A1 (en) Cyclodextrin-based polymers for therapeutic delivery
SG194175A1 (en) Polymer conjugated prostaglandin analogues
GB201105455D0 (en) Blends of a polylactic acid and a water soluble polymer
JP2017511322A5 (https=)
WO2011126839A3 (en) Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
UA101497C2 (ru) Конъюгаты фактора ix с увеличенным временем полужизни
MX2022003939A (es) Composicion farmaceutica de estabilidad mejorada.
WO2012017288A3 (en) Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair
WO2018056937A3 (en) Nanofibrous adhesion barrier
JP2016529286A5 (https=)